Discovery of a human monoclonal antibody that cross-neutralizes venom phospholipase A2s from three different snake genera

Christoffer V. Sørensen; José R. Almeida; Markus-Frederik Bohn; Esperanza Rivera de Torre; Sanne Schoffelen; Bjørn G. Voldborg; Anne Ljungars; Sakthivel Vaiyapuri; Andreas H. Laustsen

doi:10.1016/j.toxicon.2023.107307

Discovery of a human monoclonal antibody that cross-neutralizes venom phospholipase A₂s from three different snake genera

Christoffer V. Sørensen^*, José R. Almeida, Markus-Frederik Bohn, Esperanza Rivera de Torre, Sanne Schoffelen, Bjørn G. Voldborg, Anne Ljungars, Sakthivel Vaiyapuri^*, Andreas H. Laustsen^*

^*Corresponding author for this work

Department of Biotechnology and Biomedicine

University of Reading

Research output: Contribution to journal › Journal article › Research › peer-review

81 Downloads (Orbit)

Abstract

Despite the considerable global impact of snakebite envenoming, available treatments remain suboptimal. Here, we report the discovery of a broadly-neutralizing human monoclonal antibody, using a phage display-based cross-panning strategy, capable of reducing the cytotoxic effects of venom phospholipase A₂s from three different snake genera from different continents. This highlights the potential of utilizing monoclonal antibodies to develop more effective, safer, and globally accessible polyvalent antivenoms that can be widely used to treat snakebite envenoming.

Original language	English
Article number	107307
Journal	Toxicon
Volume	234
Number of pages	5
ISSN	0041-0101
DOIs	https://doi.org/10.1016/j.toxicon.2023.107307
Publication status	Published - 2023

Access to Document

10.1016/j.toxicon.2023.107307Licence: CC BY

FulltextFinal published version, 1.86 MBLicence: CC BY

OpenUrl availability

Full text

Cite this

@article{3b0cf5d99f79430aa675bef38657c0d6,

title = "Discovery of a human monoclonal antibody that cross-neutralizes venom phospholipase A2s from three different snake genera",

abstract = "Despite the considerable global impact of snakebite envenoming, available treatments remain suboptimal. Here, we report the discovery of a broadly-neutralizing human monoclonal antibody, using a phage display-based cross-panning strategy, capable of reducing the cytotoxic effects of venom phospholipase A2s from three different snake genera from different continents. This highlights the potential of utilizing monoclonal antibodies to develop more effective, safer, and globally accessible polyvalent antivenoms that can be widely used to treat snakebite envenoming.",

author = "S{\o}rensen, \{Christoffer V.\} and Almeida, \{Jos{\'e} R.\} and Markus-Frederik Bohn and \{de Torre\}, \{Esperanza Rivera\} and Sanne Schoffelen and Voldborg, \{Bj{\o}rn G.\} and Anne Ljungars and Sakthivel Vaiyapuri and Laustsen, \{Andreas H.\}",

year = "2023",

doi = "10.1016/j.toxicon.2023.107307",

language = "English",

volume = "234",

journal = "Toxicon",

issn = "0041-0101",

publisher = "Elsevier",

}

TY - JOUR

T1 - Discovery of a human monoclonal antibody that cross-neutralizes venom phospholipase A2s from three different snake genera

AU - Sørensen, Christoffer V.

AU - Almeida, José R.

AU - Bohn, Markus-Frederik

AU - de Torre, Esperanza Rivera

AU - Schoffelen, Sanne

AU - Voldborg, Bjørn G.

AU - Ljungars, Anne

AU - Vaiyapuri, Sakthivel

AU - Laustsen, Andreas H.

PY - 2023

Y1 - 2023

N2 - Despite the considerable global impact of snakebite envenoming, available treatments remain suboptimal. Here, we report the discovery of a broadly-neutralizing human monoclonal antibody, using a phage display-based cross-panning strategy, capable of reducing the cytotoxic effects of venom phospholipase A2s from three different snake genera from different continents. This highlights the potential of utilizing monoclonal antibodies to develop more effective, safer, and globally accessible polyvalent antivenoms that can be widely used to treat snakebite envenoming.

AB - Despite the considerable global impact of snakebite envenoming, available treatments remain suboptimal. Here, we report the discovery of a broadly-neutralizing human monoclonal antibody, using a phage display-based cross-panning strategy, capable of reducing the cytotoxic effects of venom phospholipase A2s from three different snake genera from different continents. This highlights the potential of utilizing monoclonal antibodies to develop more effective, safer, and globally accessible polyvalent antivenoms that can be widely used to treat snakebite envenoming.

U2 - 10.1016/j.toxicon.2023.107307

DO - 10.1016/j.toxicon.2023.107307

M3 - Journal article

C2 - 37783315

SN - 0041-0101

VL - 234

JO - Toxicon

JF - Toxicon

M1 - 107307

ER -